• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同时使用口服抗凝药和阿司匹林出血的风险:系统评价和荟萃分析。

Risk of bleeding with concomitant use of oral anticoagulants and aspirin: A systematic review and meta-analysis.

机构信息

College of Pharmacy, University of Utah, Salt Lake City, UH, USA.

Froedtert and the Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Am J Health Syst Pharm. 2024 Jun 11;81(12):494-508. doi: 10.1093/ajhp/zxae010.

DOI:10.1093/ajhp/zxae010
PMID:38263263
Abstract

PURPOSE

Oral anticoagulants (OACs) and aspirin can trigger bleeding events when used alone or in combination. The purpose of this study was to compare the risk of any type of bleeding in individuals exposed to a combination of OAC and aspirin with the risk in those taking an OAC or aspirin alone.

METHODS

MEDLINE and Web of Science were queried in January 2021 for eligible articles. Studies were included if they were either randomized controlled trials (RCTs) or observational studies and evaluated the number of any bleeding events in two groups, one with exposure to both OAC and aspirin and one with exposure to OAC alone or aspirin alone. Pooled odds ratios were calculated using a random-effects model.

RESULTS

Forty-two studies were included. In an analysis of 15 RCTs and 19 observational studies evaluating OAC plus aspirin versus OAC alone, a significant difference in the risk of bleeding was observed in the combination groups, with an odds ratio [OR] of, 1.36 (95% CI, 1.15-1.59) for RCTs and an OR of 1.42 (95% CI-, 1.09-1.87) for observational studies. When OAC plus aspirin was compared to aspirin alone, a higher rate of bleeding was found in the combination group (OR, 2.36; 95%CI, 1.91-2.92) in the analysis of 15 RCTs, but no significant difference was found among 10 observational studies (OR, 1.93; 95% Cl, 0.99-3.75).

CONCLUSION

The risk of any type of bleeding was significantly increased among patients taking aspirin plus OAC compared to those taking OAC alone in both RCTs and observational studies. Evaluation of RCTs comparing OAC plus aspirin to aspirin alone suggests increased bleeding risk as well.

摘要

目的

单独使用或联合使用口服抗凝剂 (OAC) 和阿司匹林时,都可能引发出血事件。本研究旨在比较同时使用 OAC 和阿司匹林与单独使用 OAC 或阿司匹林的个体发生任何类型出血的风险。

方法

2021 年 1 月,通过 MEDLINE 和 Web of Science 检索符合条件的文章。如果研究为随机对照试验 (RCT) 或观察性研究,并评估了两组(一组同时暴露于 OAC 和阿司匹林,一组单独暴露于 OAC 或阿司匹林)的任何出血事件数量,则纳入研究。使用随机效应模型计算汇总优势比。

结果

共纳入 42 项研究。在分析 15 项 RCT 和 19 项观察性研究评估 OAC 加阿司匹林与 OAC 单独使用的结果时,联合组的出血风险存在显著差异,RCT 的优势比(OR)为 1.36(95%CI,1.15-1.59),观察性研究的 OR 为 1.42(95%CI,1.09-1.87)。当将 OAC 加阿司匹林与阿司匹林单独比较时,在分析 15 项 RCT 时,联合组出血率更高(OR,2.36;95%CI,1.91-2.92),但在 10 项观察性研究中未发现显著差异(OR,1.93;95%Cl,0.99-3.75)。

结论

在 RCT 和观察性研究中,与单独使用 OAC 相比,同时使用阿司匹林加 OAC 的患者出血风险显著增加。比较 OAC 加阿司匹林与阿司匹林单独使用的 RCT 评估也提示出血风险增加。

相似文献

1
Risk of bleeding with concomitant use of oral anticoagulants and aspirin: A systematic review and meta-analysis.同时使用口服抗凝药和阿司匹林出血的风险:系统评价和荟萃分析。
Am J Health Syst Pharm. 2024 Jun 11;81(12):494-508. doi: 10.1093/ajhp/zxae010.
2
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者使用氯吡格雷、阿司匹林和口服抗凝剂的随机对照试验及校正观察结果的Meta分析。
Am J Cardiol. 2015 May 1;115(9):1185-93. doi: 10.1016/j.amjcard.2015.02.003. Epub 2015 Feb 12.
3
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials.心血管疾病风险患者中阿司匹林与口服抗凝剂联合治疗与单纯口服抗凝剂治疗的比较:随机试验的荟萃分析
Arch Intern Med. 2007 Jan 22;167(2):117-24. doi: 10.1001/archinte.167.2.117.
4
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.经皮冠状动脉介入治疗(PCI)后伴有心房颤动患者的口服抗凝药物转换:RE-DUAL PCI 试验亚组分析。
JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.
5
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.收支平衡成本:经皮冠状动脉介入治疗的房颤患者中加用阿司匹林对净临床影响的观点。
Cardiovasc Drugs Ther. 2024 Jun;38(3):605-619. doi: 10.1007/s10557-022-07367-3. Epub 2022 Jul 13.
6
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.口服抗凝药物治疗患者行冠状动脉支架植入术后双联与三联治疗的比较:系统评价和荟萃分析。
Int J Cardiol. 2018 Dec 15;273:80-87. doi: 10.1016/j.ijcard.2018.08.019. Epub 2018 Aug 9.
7
Comparing anticoagulation therapy alone versus anticoagulation plus single antiplatelet drug therapy after transcatheter aortic valve implantation in patients with an indication for anticoagulation: a systematic review and meta-analysis.经导管主动脉瓣置换术后有抗凝指征的患者中抗凝治疗与抗凝加单一抗血小板药物治疗的比较:系统评价和荟萃分析。
Cardiovasc Drugs Ther. 2021 Oct;35(5):995-1002. doi: 10.1007/s10557-020-07081-y. Epub 2020 Oct 8.
8
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.抗血小板和抗凝药物用于抗磷脂综合征患者中风和其他血栓栓塞事件的二级预防。
Cochrane Database Syst Rev. 2020 Oct 12;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub3.
9
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.抗血小板药物与口服抗凝剂在老年房颤患者中的出血风险比较:系统评价和荟萃分析。
J Thromb Haemost. 2017 Jul;15(7):1500-1510. doi: 10.1111/jth.13697. Epub 2017 May 11.
10
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.急性心肌梗死后老年患者中阿司匹林、噻吩并吡啶衍生物和华法林联合使用的出血并发症。
Arch Intern Med. 2005 Apr 11;165(7):784-9. doi: 10.1001/archinte.165.7.784.

引用本文的文献

1
Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System.抗凝药和抗血小板药联合使用相关的出血风险:来自美国食品药品监督管理局不良事件报告系统的见解
J Clin Med. 2025 Sep 4;14(17):6262. doi: 10.3390/jcm14176262.
2
Drug-Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross-Sectional Study.先天性心脏病患儿的药物相关副作用及相关危险因素:一项横断面研究
Health Sci Rep. 2025 May 19;8(5):e70835. doi: 10.1002/hsr2.70835. eCollection 2025 May.
3
Playbook workflow builder: Interactive construction of bioinformatics workflows.
剧本工作流程构建器:生物信息学工作流程的交互式构建
PLoS Comput Biol. 2025 Apr 3;21(4):e1012901. doi: 10.1371/journal.pcbi.1012901. eCollection 2025 Apr.
4
Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: A World Stroke Organization (WSO) scientific statement.心房颤动合并近期缺血性卒中、短暂性脑缺血发作或颅内出血患者的缺血性卒中预防:世界卒中组织(WSO)科学声明
Int J Stroke. 2025 Apr;20(4):385-400. doi: 10.1177/17474930241312649. Epub 2025 Jan 30.